Verrica Pharmaceuticals Inc VRCA

NAS: VRCA | ISIN: US92511W1080   31/05/2024
8,510 USD (+2,16%)
(+2,16%)   31/05/2024

24 februari 2024 · VERRICA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA · Persbericht

28 juli 2022 · VRCA Investors Have Opportunity to Lead Verrica Pharmaceuticals Inc. Securities Fraud Lawsuit · Persbericht

20 juli 2022 · Berger Montague Investigates Securities Fraud Allegations Against Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) - VERRICA PHARMACEUTICALS, INC. - Lead Plaintiff Deadline is August 5, 2022 · Persbericht

30 juni 2022 · VERRICA PHARMACEUTICALS, INC. Company News: Berger Montague Investigates Securities Fraud Allegations Against Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA); Lead Plaintiff Deadline is August 5, 2022 · Persbericht

16 juni 2022 · VRCA Investors Have Opportunity to Lead Verrica Pharmaceuticals Inc. Securities Fraud Lawsuit · Persbericht

17 maart 2021 · Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan · Persbericht

3 maart 2021 · Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference · Persbericht

23 februari 2021 · Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference · Persbericht

17 februari 2021 · Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum · Persbericht

19 januari 2021 · Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference · Persbericht

Mijn selecties